Therapeutics and Diagnostics for Women's Disorders

영문목차

Abstract

Highlights

• Covers a wide variety of products and disorders that predominantly affect women including autoimmune diseases, women' s cancer, gynecological infections and diseases, reproductive-related therapies and diagnostics, rheumatoid arthritis and osteoporosis
• Includes U.S. market forecasts for therapeutics and diagnostics for women' s disorders through 2014
• Provides detailed information based on product categories and their use
• Discusses new therapeutics and diagnostics that have emerged and have a significant impact on women' s health
• Profiles leading companies.

SCOPE OF REPORT

This newly updated BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the market for women' s therapeutic and diagnostic products. The geographical scope of this study is U.S. based.

• Autoimmune diseases
• Women' s cancer
• Gynecological diseases and infections
• Kidney and urological diseases and infections
• Reproductive-related therapies and diagnostics
• Rheumatoid arthritis and osteoporosis
• Each market segment provides detailed information based on product categories, use of products, forecasts, and competitive analyses.

METHODOLOGY

The information for this BCC Research report was obtained through primary and secondary data collection methods. Primary methods included interviews with more than 50 key executives, product managers, clinical specialists and other related key personnel involved in the women' s healthcare industry. Secondary sources included published literature, investment reports, company literature, and various business journals that have emphasis on women' s health and related areas.

Market data for this report pertains to the U.S. market and uses U.S. dollars at the manufacturers' level. The base year of the report is 2008, with historical data provided for 2006 and 2007, and forecast data provided for 2013. Historical, base year and forecast data are provided for each market segment of the report. Growth rates are determined through a compilation of data including past trends, future trends, demographics, incidence, mortality, products in research and development, and current product growth, etc. Competitor market share estimates are provided for each market segment for the 2008 base year.

Table of Contents

Therapeutics and Diagnostics for Women' s Disorders

Chapter-1: SUMMARY

• CHAPTER TWO: SUMMARY
• SUMMARY TABLE U.S. MARKET FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN' S DISORDERS BY SEGMENT, THROUGH 2013 ($ MILLIONS)
• SUMMARY FIGURE U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN' S DISORDERS BY SEGMENT, 2006 - 2013 ($ MILLIONS)

Chapter-2: INDUSTRY OVERVIEW

• DEFINITION OF WOMEN' S DISORDERS
• IMPORTANCE OF THE INDUSTRY AND DEMOGRAPHICS
  • TABLE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)
  • FIGURE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)
  • TABLE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
  • FIGURE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
  • TABLE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
  • FIGURE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
• HISTORY OF THE INDUSTRY AND RESPONSE TO WOMEN' S HEALTHCARE NEEDS
• REGULATORY ENVIRONMENT
• EFFECTS OF AGING
  • FIGURE 4 FEMALE LIKELIHOOD OF GETTING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2008 (%)
  • FIGURE 4 (CONTINUED)
• CONTRACEPTIVE INSURANCE COVERAGE
  • TABLE 4 INSURANCE COVERAGE OF CONTRACEPTIVES BY STATE
• CONTRACEPTIVE USE IN TEENS INCREASES
• NEW USE FOR CONTRACEPTIVES
• NEW USE FOR CONTRACEPTIVES (CONTINUED)
• AGING AND INFERTILITY
• CONTRACEPTIVE PATCH LINKED TO DEATHS
• WOMEN AND SEXUAL HEALTH
• WOMEN AND SEXUAL HEALTH (CONTINUED)
• INCIDENCE OF SEXUAL DYSFUNCTION
• Incidence of Sexual Dysfunction (Continued)
• VASCULAR TREATMENTS AND SEXUAL DYSFUNCTION
• DIAGNOSTICS
• NEW DEVELOPMENTS IN SEXUAL DYSFUNCTION TREATMENTS FOR WOMEN
• Alista
  • TABLE 5 U.S. SEXUAL DYSFUNCTION PRODUCTS FOR WOMEN IN DEVELOPMENT, 2008
• SEXUAL DYSFUNCTION IN CANCER
• INFERTILITY AND CANCER
• CHEMOTHERAPY
• RADIATION
• PREVENTION STRATEGIES
• MARKETING AND WOMEN
• COUNTERFEIT PHARMACEUTICALS
• GENERIC PARTICIPATION
  • TABLE 6 U.S. PRESCRIPTION GENERIC DRUG APPROVALS FOR CONSTRACEPTION BY COMPANY AND APPROVAL DATE, 2003 - 2008
• INTERNATIONAL ISSUES

Chapter-3: AUTOIMMUNE DISEASES

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 7 U.S. MARKET FORECAST FOR AUTOIMMUNE DISEASES BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 8 MANUFACTURERS OF AUTOIMMUNE DISEASE PRODUCTS, 2008
  • TABLE 9 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)
  • FIGURE 5 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 (%)
• MARKET BY DISEASE TYPE
• CHRONIC FATIGUE SYNDROME
• Incidence and Mortality
• Market Indicators
• Market Indicators (Continued)
• Market Indicators (Continued)
• FIBROMYALGIA
• Incidence
• Diagnostics
• Pain in 11 of 18 Tender Point Sites on Digital Palpation
• Pain in 11 of 18 ..... (Continued)
• Market Indicators
• Market Indicators (Continued)
• Current Market Participants
• MYASTHENIA GRAVIS
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Current Market Participants
• SJOGREN' S SYNDROME
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Current Market Participants
• SYSTEMIC LUPUS ERYTHEMATOSUS
• Systemic Lupus ..... (Continued)
• Incidence and Mortality
• Diagnostics
• Diagnostics (Continued)
• Market Indicators
• IN DEVELOPMENT
• PRESTARA
• AMPLIGEN
• RIQUENT
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 10 U.S. AUTOIMMUNE DISEASE PRODUCTS IN DEVELOPMENT, 2008
  • TABLE 10 (CONTINUED)

Chapter-4: WOMEN' s CANCERS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 11 U.S. MARKET FORECAST FOR WOMEN' S CANCER BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 12 MANUFACTURERS OF WOMEN' S CANCER PRODUCTS, 2008
  • TABLE 13 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)
  • FIGURE 6 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 (%)
• MARKET BY TYPE OF CANCER
• BREAST CANCER
  • TABLE 14 TNM CLASSIFICATIONS OF BREAST CANCERS
  • TABLE 15 5-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2008 (%)
• Incidence and Mortality
  • TABLE 16 TOTAL YEARLY CASES AND DEATHS FOR BREAST CANCER IN WOMEN WORLDWIDE, 2008
• Diagnostics
• Diagnostics (Continued)
• Market Indicators
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Current Market Participants
• CERVICAL CANCER
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Current Market Participants
• ENDOMETRIAL CANCER
• Incidence and Mortality
• Market Indicators
• Current Market Participants
• OVARIAN CANCER
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Market Indicators (Continued)
• Current Market Participants
• IN DEVELOPMENT
• 572016
• ACTIMMUNE
• ARZOXIFENE
• ATAMESTANE
• FASLODEX
• IMC-C2259
• FABLYN
• OVAREX
• TEMSIROLIMUS
• THERATOPE
• OPAXIO
• A FEW SELECT U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 17 SELECTED WOMEN' S CANCER PRODUCTS IN DEVELOPMENT IN THE U.S., 2008

Chapter-5: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

• U.S. MARKET OVERVIEW
  • TABLE 18 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS
• MARKET SIZE
  • TABLE 19 U.S. MARKET FORECAST FOR GYNECOLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 20 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 7 SUMMARY OF U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUES, 2008 (%)
  • TABLE 21 MANUFACTURERS OF GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS, 2008
  • TABLE 21 (CONTINUED)
• MARKET BY DISEASE TYPE
• BACTERIAL VAGINOSIS
• Incidence
• Market Indicators
• CANDIDIASIS
• Incidence
• Market Indicators
• Current Market Participants
• CERVICAL DYSPLASIA
• Incidence
• CHLAMYDIA
• Incidence
• Diagnostics
• Market Indicators
• CONDYLOMA
• Incidence
• Market Indicators
• DYSMENORRHEA
• Incidence
• ENDOMETRIOSIS
• Incidence
• Market Indicators
• FIBROIDS
• Incidence
• Market Indicators
• GENITAL HERPES
• Incidence
• Diagnostics
• Market Indicators
• Current Market Participants
• PELVIC INFLAMMATORY DISEASE
• Incidence
• Market Indicators
• IN DEVELOPMENT
• HUMAN PAPILLOMAVIRUS
• LOW DOSE ORAL INTERFERON-ALPHA
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 22 GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
  • TABLE 22 (CONTINUED)

Chapter-6: KIDNEY AND UROLOGIC DISEASES AND CONDITIONS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 23 U.S. MARKET FORECAST FOR KIDNEY AND UROLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 24 U.S. KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 8 SUMMARY OF KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUES, 2008 (%)
  • TABLE 25 MANUFACTURERS OF KIDNEY AND UROLOGIC DISEASE AND CONDITION PRODUCTS, 2008
• MARKET BY DISEASE TYPE
• URINARY TRACT INFECTIONS
• Incidence
• Diagnostics
• Market Indicators
• Market Indicators (Continued)
• URINARY INCONTINENCE
• Incidence
• Market Indicators
• Current Market Participants
  • TABLE 26 U.S. URINARY INCONTINENCE/OVERACTIVE BLADDER MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• URINARY INTERSTITIAL CYSTITIS
• Incidence
• Market Size and Growth
• IN DEVELOPMENT
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 27 KIDNEY AND UROLOGICAL DISEASE AND CONDITIONS PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
  • TABLE 27 (CONTINUED)

Chapter-7: REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 28 U.S. MARKET FORECAST FOR REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 29 U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 9 SUMMARY OF U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUES, 2008 (%)
• MARKET BY TYPE
• CONTRACEPTION
  • TABLE 30 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)
  • FIGURE 10 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)
• Market Indicators
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Most Commonly Used Oral Contraceptives
  • TABLE 31 MOST COMMONLY USED ORAL CONTRACEPTIVES IN THE U.S., 2008
  • TABLE 31 (CONTINUED)
• Most Commonly ..... (Continued)
• Current Market Participants
  • TABLE 32 U.S. CONTRACEPTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• INFERTILITY
• Incidence
• Market Indicators
• Hormonal Therapy
• Hormonal Therapy (Continued)
• Surgical Treatment
• Artificial Insemination
• Assisted Reproductive Technology
• Current Market Participants
  • TABLE 33 U.S. INFERTILITY MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• MENOPAUSE
• Incidence
• Market Indicators
• Most Commonly Used Menopause Treatment Products
  • TABLE 34 MOST COMMONLY USED MENOPAUSE TREATMENT PRODUCTS 2008
• Most Commonly ..... (Continued)
• Current Market Participants
  • TABLE 35 U.S. MENOPAUSE MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• IN DEVELOPMENT
• BAZEDOXIFENE/CONJUGATED ESTROGENS
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 36 REPRODUCTIVE-RELATED PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
  • TABLE 36 (CONTINUED)

Chapter-8: RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 37 U.S. MARKET FORECAST FOR RHEUMATOID ARTHRITIS AND OSTEOPOROSIS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 38 U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 11 SUMMARY OF U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUES, 2008 (%)
  • TABLE 39 MANUFACTURERS OF RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS, 2008
  • TABLE 39 (CONTINUED)
• MARKET BY TYPE
• RHEUMATOID ARTHRITIS
• Incidence
• Market Indicators
• Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs
• Cox-2 Inhibitors
• Disease-Modifying Anti-Rheumatic Drugs
• Immunosuppressants
• Corticosteroids
• Tumor Necrosis Factor Blocker
• B-lymphocyte-Restricted Differentiation Antigen (CD20) Inhibitor
• Selective Costimulation Modulator
• Current Market Participants
  • TABLE 40 U.S. RHEUMATOID ARTHRITIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• OSTEOPOROSIS
• Incidence
• Diagnostics
• Diagnostics (Continued)
• Market Indicators
• Market Indicators (Continued)
• Current Market Participants
  • TABLE 41 U.S. OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• IN DEVELOPMENT
• PREXIGE
• REMICADE
• PREOS
• ARZOXIFENE
• FABLYN
• U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 42 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS IN DEVELOPMENT IN U.S., 2008
  • TABLE 42 (CONTINUED)

Chapter-9: MARKET SUMMARY

• U.S. WOMEN' S HEALTHCARE MARKET ANALYSIS
  • TABLE 43 U.S. WOMEN' S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)
  • FIGURE 12 U.S. WOMEN' S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)

Chapter-10: INDUSTRY PARTICIPANTS BY TYPE

• TABLE 44 MAJOR WOMEN' S HEALTHCARE INDUSTRY PARTICIPANTS, BY PRODUCT TYPE, 2008
• TABLE 44 (CONTINUED)
• SELECTED COMPANY PROFILES
• ASTRAZENECA
• BARR LABORATORIES, INC.
• Barr Laboratories, Inc. (Continued)
• BRISTOL-MYERS SQUIBB CO.
• ELI LILLY & CO.
• GENENTECH
• GLAXOSMITHKLINE
• MERCK & CO., INC.
• ORTHO-MCNEIL PHARMACEUTICALS
• PFIZER
• SERONO INTERNATIONAL S.A.
• WYETH
• LIST OF COMPANIES
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)

관련자료

추천 보고서

BCC Research사 연간정보서비스

BCC RESEARCH Market Research Report Subscription Package

출판일:

BCC Research사의 바이오테크놀러지관련 보고서

세계의 키랄 기술 시장 : 유럽

Global Markets for Chiral Technology -- Focus on Europe

가격: USD 3,900

출판일: 2012년 05월

세계의 키랄 기술 시장 : 미국

Global Markets for Chiral Technology -- Focus on the U.S.

가격: USD 3,900

출판일: 2012년 05월

세계의 바이오테크놀러지 부문 배지, 혈청, 시약 시장

Global Markets for Media, Sera and Reagents in Biotechnology

가격: USD 4,850

출판일: 2012년 04월

메일링 서비스

관심 분야의 최신 보고서 및 컨퍼런스 정보를 이메일로 받아볼 수 있는 서비스 입니다.